



2013-12-02

PRESS RELEASE

## Nexttobe extends loan to Oasmia

The investment company Nexttobe AB extends its MSEK 105 loan to Oasmia AB. The loan is due December 31, 2014 and the carried interest for the period 2014-01-01 to 2014-12-31 is set to 8.5 % Nexttobe is Oasmia's second largest owner after Alseco International S.A. with 21.57 % of the shares in the company.

For further information, please contact:  
Mikael Widell, Vice President Communications  
Tel: +46 70 311 99 60  
E-mail: [mikael.widell@oasmia.com](mailto:mikael.widell@oasmia.com)

### About Oasmia Pharmaceutical AB

Oasmia Pharmaceutical AB develops new generations of drugs in the field of human and veterinary oncology. The company's product development aims to create and manufacture novel nanoparticle formulations and drug-delivery systems based on well-established cytostatics which, in comparison with current alternatives, show improved properties, reduced side-effects, and expanded applications. The company's product development is based on its proprietary in-house research and company patents. Oasmia is listed on NASDAQ OMX Stockholm (OASM) and the Frankfurt Stock Exchange (OMAX, ISIN SE0000722365).

---

For more information, please contact: Mikael Widell, Vice President Communications, Oasmia Pharmaceutical AB. E-mail: [press@oasmia.com](mailto:press@oasmia.com) Phone: +46 (0) 18 50 54 40. Information is also available at [www.oasmia.com](http://www.oasmia.com) [www.nasdaqomxnordic.com](http://www.nasdaqomxnordic.com) [www.boerse-frankfurt.de](http://www.boerse-frankfurt.de) [twitter.com/oasmia](http://twitter.com/oasmia)

"Oasmia is required under the Financial Instruments Trading Act to make the information in this press release public. The information was submitted for publication at 09.00, CET on December 2, 2013."